scPharmaceuticals. has been granted a patent for a liquid pharmaceutical formulation containing furosemide, excipients, and a buffer. This formulation is designed to treat conditions such as congestion, edema, fluid overload, or hypertension, with specific concentrations and pH levels outlined in the claims. GlobalData’s report on scPharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on scPharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. scPharmaceuticals's grant share as of July 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12048709B2 outlines a unit liquid pharmaceutical formulation primarily containing furosemide, a diuretic used to treat conditions such as congestion, edema, fluid overload, and hypertension. The formulation includes furosemide in amounts ranging from 10 mg to 200 mg, along with pharmaceutically acceptable excipients and a buffer, specifically tromethamine, at concentrations between 25 mM and 150 mM. The pH of the formulation is maintained between 6.5 and 8.5, with specific claims detailing variations in the concentration of furosemide, the inclusion of benzyl alcohol as an excipient, and the potential addition of other components like water, pH adjusters, and osmolarity adjusters.
Additionally, the patent describes methods for administering the formulation, including subcutaneous injection, and outlines the creation of kits containing one or more units of the formulation. The volume of the liquid formulation can range from 0.5 mL to 10 mL, with options for pre-loading in various medical devices such as syringes and autoinjectors. The claims also specify the potential use of polysorbate and other excipients to enhance the formulation's stability and efficacy. Overall, the patent provides a comprehensive framework for a liquid pharmaceutical product designed for effective therapeutic use in managing fluid-related medical conditions.
To know more about GlobalData’s detailed insights on scPharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.